Funding for this research was provided by:
Sanofi
Berit Linnea and Ragnar Bakken Foundation
University of Gothenburg
Article History
Accepted: 10 January 2023
First Online: 2 February 2023
Declarations
:
: The study was an investigater-sponsored study funded by Sanofi and supported by grants from Berit Linnea and Ragnar Bakken Foundation. Open access funding was provided by University of Gothenburg.
: JL has received lecture honoraria from Biogen, BMS, Celgene, Janssen, Merck, Novartis, Sanofi, Roche and Alexion; has served on scientific advisory boards for Biogen, BMS, Merck, Novartis, Sanofi, Roche and Alexion; serves on the editorial board of the Acta Neurologica Scandinavica; and has received unconditional research grants from Biogen and Novartis. HF and AN: no conflict of interest.
: On request, through email contact, original data can be provided by the corresponding author.
: This study was approved by the regional ethical review board of Gothenburg, Sweden (diary number 773-17) and registered in ClinicalTrials.gov (Identifier: NCT04129736 (ExternalRef removed NCT04129736)). The study was performed in accordance with the ethical standards as laid down in the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards.
: All patients participated voluntary in this study and informed consent was obtained from all subjects.
: Not applicable.
: JL conceptualised and planned the study, collected data, wrote and contributed intellectually to the manuscript. HF analysed biomarkers in plasma and cerebrospinal fluid, reviewed and contributed intellectually to the manuscript. AN collected the data, performed the analytic calculations and compiled the figures, reviewed and contributed intellectually to the manuscript.
: Not applicable.